ArticleJournal of neuro-oncology2011
Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.
Article in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.Neuro-oncology · 2025Pooled it
- The role of bevacizumab for treatment-refractory intracranial meningiomas: a single institution's experience and a systematic review of the literature.Acta neurochirurgica · 2022Pooled it
- A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.Journal of neuro-oncology · 2014Trial
- Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.Journal of neuro-oncology · 2012Trial
- The role of radiation therapy and systemic treatments in meningioma: The present and the future.Cancer medicine · 2023Review
- Signaling pathways in brain tumors and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand?Cancers · 2022Review
- Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets.Diagnostics (Basel, Switzerland) · 2021Review
- Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas.CNS oncology · 2021Review
- Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management.Frontiers in oncology · 2020Review
- Multimodality Therapy of Patients with Refractory Meningiomas.Current treatment options in oncology · 2019Review
- An overview of meningiomas.Future oncology (London, England) · 2018Review
- Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review.Surgical neurology international · 2018Review
- The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas.Brain tumor research and treatment · 2017Article
- Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution.Journal of neuro-oncology · 2017Article
- Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.Neuro-oncology · 2014Review
- Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity.Cancer research · 2013Article
- IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series.CNS oncology · 2013Article
- Medical management of meningiomas.CNS oncology · 2013Review
- Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma?CNS oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature. A retrospective case series of 60 patients with recurrent WHO grade 1 meningioma treated with HU following progression after surgery and radiotherapy was conducted with primary study objective progression free survival (PFS) at 6- and 12-months. Sixty patients (45 women; 15 men: median age 61.5 years, range 26-88) with recurrent meningioma were treated with HU (1000 mg/m(2)/day orally divided twice per day; one cycle operationally defined as 4-weeks of daily HU). All patients had progressed radiographically after prior therapy with surgery (60/60) and radiotherapy (external beam radiotherapy 60/60; stereotactic radiotherapy 53/60). No patient received prior chemotherapy or targeted therapy before instituting HU. Patients received 1-12 cycles (median 2.0) of HU with modest toxicity (10% grade 3 + anemia or fatigue). There were no radiographic responses, 35% of patients had stable disease and 65% manifested progressive disease. Duration of stable disease ranged from 3 to 12 months (median 4.0 months). The overall PFS was 10% (median PFS 2.0 months). The majority of patients (80%) following progression on HU were subsequently treated on an investigational trial. In this retrospective case series, HU though generally well tolerated and convenient, appeared to have very limited activity which raises questions of what constitutes effective salvage therapy and indicates an unmet need for alternative treatments for recurrent meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.